The eradication of cancer remains a vexing problem despite recent advances in our
understanding of the molecular basis of neoplasia. One therapeutic approach that has …

Avidin-biotin interaction is one of the strongest non-covalent interactions in the nature.
Avidin and its analogues have therefore been extensively utilized as probes and affinity …

Despite overall improvements in outcomes of diffuse large B-cell lymphoma (DLBCL),
approximately one-third of patients will develop relapsed/refractory disease that remains a …

Treatment of B-cell non-Hodgkin's lymphoma has become more successful, largely owing to
the availability of therapeutic monoclonal antibodies, which may avoid the toxic effects of …

Conventional external-beam radiation therapy is dedicated to the treatment of localized
disease, whereas radioimmunotherapy represents an innovative tool for the treatment of …

The first description of cancer is found in an Egyptian papyrus and dates back to
approximately 1600 BC. It was regarded as an incurable disease until the nineteenth …

Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a
chemotherapy-based transplantation regimen followed by autologous hematopoietic cell …

Abstract Purpose To evaluate whether 89 Zr can be used as a PET surrogate label for
quantification of 90 Y-ibritumomab tiuxetan (90 Y-Zevalin) biodistribution and dosimetry …

Introduction Radionuclide therapy has distinct similarities to, but also profound differences
from external radiotherapy. Review This review discusses techniques and results of …

Purpose This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y)
ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan …